Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B brings in CHF44mm for Evolva

Executive Summary

Evolva Biotech SA (developing compounds for renal, metabolic, cardiovascular, and infectious diseases) has raised CHF44mm ($42.7mm) with the closing of its Series B venture round. Current backer Aravis led and was joined by fellow shareholders BioMedInvest, Astellas Venture, Dansk Innovation, Novartis BioVenture Fund, Vinci Capital, and Sunstone Capital. New investors Entrepreneurs Fund, Auriga Partners, Vinci Capital & Renaissance PME, and Wellington Partners also participated. Evolva will use the funds for its merger with fellow Swiss biotech Arpida.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Synthesis Technologies, Production Processes
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies